Molecular subtyping based on proteomic and phosphoproteomic data ignores the influence of genetic background, simplifies tumor heterogeneity characterization, and provides potential biomarkers and therapeutic targets for each subtype with APC mutations (16, 17, 18, 19). This evidence concerns the gene APC and neoplasm.